(D61.1) Drug-induced aplastic anaemia

More details coming soon

Icon
491 888 in individuals diagnosis drug-induced aplastic anaemia confirmed
Icon
42 998 deaths with diagnosis drug-induced aplastic anaemia
Icon
9% mortality rate associated with the disease drug-induced aplastic anaemia

Diagnosis drug-induced aplastic anaemia is diagnosed Men are 6.82% more likely than Women

262 713

Men receive the diagnosis drug-induced aplastic anaemia

22 092 (8.4 %)

Died from this diagnosis.

100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
229 175

Women receive the diagnosis drug-induced aplastic anaemia

20 906 (9.1 %)

Died from this diagnosis.

Risk Group for the Disease drug-induced aplastic anaemia - Men and Women aged 65-69

Icon
In Men diagnosis is most often set at age 0-94
Icon
Less common in men the disease occurs at Age 95+in in women, the disease manifests at any age
Icon
In Women diagnosis is most often set at age 0-95+

Disease Features drug-induced aplastic anaemia

Icon
Absence or low individual and public risk
Icon

Drug-induced aplastic anaemia - what does this mean

More details coming soon

What happens during the disease - drug-induced aplastic anaemia

Drug-induced aplastic anaemia is caused by the suppression of the bone marrow's ability to produce new blood cells, which is caused by the direct toxic effect of a drug on the stem cells responsible for producing the new cells. this leads to a decrease in the number of red blood cells, white blood cells, and platelets, resulting in anaemia, increased risk of infection, and increased risk of bleeding.

Clinical Pattern

More details coming soon

How does a doctor diagnose

More details coming soon

Treatment and Medical Assistance

More details coming soon
Icon
17 Days of Hospitalization Required
Icon
Average Time for Outpatient Care Not Established

Drug-induced aplastic anaemia - Prevention

Drug-induced aplastic anaemia can be prevented by avoiding the use of drugs known to cause aplastic anaemia, such as anticonvulsants, antibiotics, and non-steroidal anti-inflammatory drugs. patients should also be monitored for early signs and symptoms of the condition and seek medical advice if any are present.